Detalle Publicación

ARTÍCULO
Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study
Autores: Sadaba Díaz de Rada, María Belén (Autor de correspondencia); Azanza Perea, José Ramón; Garcia-Bea, A.; Labeaga, L.; Campo, C. ; Valiente, R.
Título de la revista: EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
ISSN: 0378-7966
Volumen: 45
Número: 2
Páginas: 265 - 272
Fecha de publicación: 2020
Lugar: WOS
Resumen:
Background and Objective Bilastine is a non-sedating H1 antihistamine indicated for the treatment of allergic rhinoconjunctivitis and urticaria. The aim of this trial was to assess the bioequivalence of three novel pediatric oral formulations of bilastine. Methods An open label, randomized, four-treatment-period, four-sequence, crossover, single-center study was conducted in 23 healthy volunteers. Each subject received four single doses of bilastine under fasting conditions: a 10-mg orodispersible tablet (DT1), a 10-mg oral solution (SOL), a 10-mg orodispersible tablet without water (DT2dry), and a 10-mg orodispersible tablet with water (DT2water, reference formulation). Blood samples were collected during 72 h with a washout period of at least 7 days. Bilastine maximum plasma concentration (C-max) and area under the plasma concentration-time curve between 0 to t time (AUC(0-t)) were calculated to assess bioequivalence. Tolerability was evaluated throughout the study. Results The three oral pediatric formulations tested were bioequivalent to the reference formulation as determined by the ratio test/reference of the geometric mean and their 90% confidence intervals (between 0.80 and 1.25) for the C-max, AUC(0-t) and AUC(0-infinity.) Bilastine was well tolerated when administered indistinctly as an orodispersible tablet or as an oral solution. Conclusion The three oral pediatric formulations tested were found to be bioequivalent to the reference formulation. All formulations were well tolerated.